WALTHAM, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today that it will release its first quarter 2015 financial results on Wednesday, May 6, 2015.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. EDT on Wednesday, May 6, 2015 to discuss the results, and give an update on the Company's progress.
|Conference Call Information:|
|Date: Wednesday, May 6, 2015|
|Time: 7:30 a.m. EDT|
|Domestic Dial-in Number: 1-877-705-6003|
|International Dial-in Number: 1-201-493-6725|
|Live webcast: http://public.viavid.com/index.php?id=114289|
For those unable to participate in the conference call or live webcast, a replay will be available beginning May 6, 2015 at 10:30 a.m. EDT until June 6, 2015 at 11:59 p.m. EDT. To access the replay, dial 1-877-870-5176. The replay passcode is 13608030.
A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 30 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 email@example.comSource:Radius Health